Leland Gershell
Stock Analyst at Oppenheimer
(4.42)
# 311
Out of 4,924 analysts
139
Total ratings
46.09%
Success rate
24.81%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $110 | $82.07 | +34.03% | 9 | Aug 7, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $60 → $61 | $45.40 | +34.36% | 3 | Aug 6, 2025 | |
| ALNY Alnylam Pharmaceuticals | Upgrades: Outperform | $490 | $430.06 | +13.94% | 8 | Aug 4, 2025 | |
| LXEO Lexeo Therapeutics | Initiates: Outperform | $20 | $4.80 | +317.10% | 1 | Jul 31, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $76 → $110 | $89.61 | +22.76% | 2 | Jul 10, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Outperform | $43 → $22 | $7.74 | +184.24% | 5 | Jun 23, 2025 | |
| ASND Ascendis Pharma | Maintains: Outperform | $215 → $224 | $184.80 | +21.21% | 12 | Jun 13, 2025 | |
| URGN UroGen Pharma | Maintains: Outperform | $10 → $31 | $18.75 | +65.33% | 11 | Jun 13, 2025 | |
| CLYM Climb Bio | Initiates: Outperform | $10 | $1.75 | +471.43% | 1 | Jun 6, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Outperform | $6 → $7 | $6.58 | +6.38% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $704 → $708 | $674.23 | +5.01% | 7 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $10 | $1.71 | +485.10% | 1 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $20 | $7.17 | +178.94% | 3 | Mar 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $98 | $60.03 | +63.25% | 3 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $52 | $20.25 | +156.79% | 2 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.39 | +1,183.04% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.90 | - | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $53 | $16.21 | +226.96% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $3.82 | +685.34% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $2.19 | +447.95% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $0.04 | +62,400.00% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $17.14 | +63.36% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $3.11 | +703.86% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $28.65 | +154.84% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $2.95 | +577.97% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.38 | +49.64% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $8.80 | +297.73% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $0.78 | +1,177.14% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.07 | +1,769.16% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.53 | +752.46% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $120 | $1.59 | +7,447.17% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $3.60 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $360,000 | $0.56 | +64,285,614.29% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $16.38 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.68 | +2,876.19% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $15.05 | - | 5 | Mar 31, 2020 |
Soleno Therapeutics
Aug 7, 2025
Maintains: Outperform
Price Target: $105 → $110
Current: $82.07
Upside: +34.03%
BridgeBio Pharma
Aug 6, 2025
Maintains: Outperform
Price Target: $60 → $61
Current: $45.40
Upside: +34.36%
Alnylam Pharmaceuticals
Aug 4, 2025
Upgrades: Outperform
Price Target: $490
Current: $430.06
Upside: +13.94%
Lexeo Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $20
Current: $4.80
Upside: +317.10%
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $76 → $110
Current: $89.61
Upside: +22.76%
Capricor Therapeutics
Jun 23, 2025
Maintains: Outperform
Price Target: $43 → $22
Current: $7.74
Upside: +184.24%
Ascendis Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $215 → $224
Current: $184.80
Upside: +21.21%
UroGen Pharma
Jun 13, 2025
Maintains: Outperform
Price Target: $10 → $31
Current: $18.75
Upside: +65.33%
Climb Bio
Jun 6, 2025
Initiates: Outperform
Price Target: $10
Current: $1.75
Upside: +471.43%
Xeris Biopharma Holdings
May 9, 2025
Maintains: Outperform
Price Target: $6 → $7
Current: $6.58
Upside: +6.38%
May 9, 2025
Maintains: Outperform
Price Target: $704 → $708
Current: $674.23
Upside: +5.01%
Mar 24, 2025
Initiates: Outperform
Price Target: $10
Current: $1.71
Upside: +485.10%
Mar 11, 2025
Maintains: Outperform
Price Target: $12 → $20
Current: $7.17
Upside: +178.94%
Feb 24, 2025
Upgrades: Outperform
Price Target: $98
Current: $60.03
Upside: +63.25%
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.25
Upside: +156.79%
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.39
Upside: +1,183.04%
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.90
Upside: -
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $16.21
Upside: +226.96%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $3.82
Upside: +685.34%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $2.19
Upside: +447.95%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $0.04
Upside: +62,400.00%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $17.14
Upside: +63.36%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $3.11
Upside: +703.86%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $28.65
Upside: +154.84%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $2.95
Upside: +577.97%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.38
Upside: +49.64%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $8.80
Upside: +297.73%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $0.78
Upside: +1,177.14%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.07
Upside: +1,769.16%
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.53
Upside: +752.46%
Mar 24, 2023
Maintains: Outperform
Price Target: $150 → $120
Current: $1.59
Upside: +7,447.17%
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $3.60
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $360,000
Current: $0.56
Upside: +64,285,614.29%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $16.38
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $1.68
Upside: +2,876.19%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $15.05
Upside: -